Overview

• Counterfeit and unauthorized compounded versions of GLP-1 drugs, including Ozempic and Wegovy, have proliferated online due to high demand and limited supply.
• The FDA has reported 14 deaths and 144 hospitalizations linked to compounded semaglutide, prompting calls for stricter regulation of copycat drugs.
• Scammers are leveraging social media platforms and websites to sell fake or unauthorized weight-loss drugs, often defrauding consumers through deceptive practices.
• Telehealth companies and compounding pharmacies operate in a regulatory gray area, with some legitimate providers alongside numerous fraudulent or unsafe operators.
• Pharmaceutical giants Eli Lilly and Novo Nordisk are increasing production and advocating for expanded insurance coverage, but shortages and high costs continue to drive consumers toward risky alternatives.